hexadecyl N,N-dimethylaminoacetate | 247231-52-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: hexadecyl N,N-dimethylaminoacetate
• 英文别名: Hexadecyl 2-(dimethylamino)acetate
• CAS: 247231-52-3
• 化学式: C₂₀H₄₁NO₂
• 分子量: 327.551
• InChiKey: HEMAWXFGPCRDIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  23
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  hexadecyl N,N-dimethylaminoacetate 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 以 水 为溶剂， 生成
  参考文献：
  名称：

  DEHYDRATING CONDENSATION AGENT HAVING PROPERTY OF ACCUMULATING AT INTERFACE WITH WATER

  摘要：

  公开号：

  EP1714962B1
• 作为产物：
  描述：

  1-十六烷醇 、 N,N-二甲基甘氨酸盐酸盐 在 4-二甲氨基吡啶 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以44%的产率得到hexadecyl N,N-dimethylaminoacetate
  参考文献：
  名称：

  在脂肪酸盐的胶束界面上双分子脱氢缩合形成酰胺的异常速率增加。

  摘要：

  DOI：

  10.1002/anie.200502594

文献信息

• Contrast agents
  申请人：——

  公开号：US20040146462A1

  公开（公告）日：2004-07-29

  Ultrasonic visualisation of a subject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration and can therefore act as deposited perfusion tracers. The preparations comprise an injectable aqueous medium comprising dispersed gas and an injectable oil-in-water emulsion in which the oil phase comprises a diffusible component capable of diffusion in vivo into the dispersed gas to promote temporary growth thereof, such that material present at the surfaces of the dispersed gas phase and material present at the surfaces of the dispersed oil phase have affinity for each other, e.g. as a result of having opposite charges. In cardiac perfusion imaging the preparations may advantageously be coadministered with vasodilator drugs such as adenosine in order to enhance the differences between return signal intensity from normal and hypoperfused myocardial tissue respectively.

  使用新型含气对比剂制剂进行超声成像，特别是心肌和其他组织的灌注成像，这些制剂促进体内气相的可控、暂时性生长，因此可以作为沉积的灌注示踪剂。这些制剂包括可注射的水性介质，其中包含分散的气体和可注射的油水乳液，其中油相包含可扩散的成分，能够在体内扩散到分散的气体中促进其暂时性生长，使分散气体相和分散油相表面的物质互相吸引，例如由于具有相反的电荷。在心脏灌注成像中，这些制剂可以优势地与血管扩张药物（如腺苷）同时使用，以增强正常和低灌注心肌组织的回波信号强度差异。
• Molecular Aggregate Capable of Undergoing Phase Transition by Dehydrating Condensation and Method of Phase Transition Thereof
  申请人：Kunishima Munetaka

  公开号：US20090023003A1

  公开（公告）日：2009-01-22

  Provided is a bilayer membrane vesicle capable of undergoing a phase transition. The bilayer membrane vesicle includes: (a) a fatty acid salt having 6 to 20 carbon atoms; (b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and (c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane. Preferably, this bilayer membrane vesicle further contains (d) a tertiary amine as a component of the membrane. Also provided is a method of inducing a phase transition of a bilayer membrane vesicle, the method including the step of adding a dehydrating condensing agent or a dehydrating condensing agent precursor having the property of accumulating at an interface to the bilayer membrane vesicle. By causing the lipids that form a molecular aggregate to chemically change, it is possible to change the physical property and the morphology of the molecular aggregate and control the timing of phase transitions such as membrane fusion. In the membrane fusion, for example, fusion can occur without leakage of the contents of the bilayer membrane vesicle.

  提供的是一种能够经历相变的双层膜囊泡。该双层膜囊泡包括：(a)一种含有6到20个碳原子的脂肪酸盐；(b)一种具有6到20个碳原子的脂肪链的醇或胺化合物；以及(c)一种能够形成双层膜的人工合成脂质或磷脂。最好的情况下，这种双层膜囊泡还包含(d)作为膜组分的三级胺。还提供了一种诱导双层膜囊泡相变的方法，该方法包括向双层膜囊泡中加入具有在界面处积聚性质的脱水缩合剂或脱水缩合剂前体的步骤。通过使形成分子聚集体的脂质发生化学变化，可以改变分子聚集体的物理性质和形态，并控制膜融合等相变的时机。在膜融合中，例如，可以在不泄漏双层膜囊泡内容物的情况下进行融合。
• Method of Inducing a Phase Transition of a Bilayer Membrane Vesicle
  申请人：JAPAN SCIENCE AND TECHNOLOGY AGENCY

  公开号：US20130251788A1

  公开（公告）日：2013-09-26

  Provided is a bilayer membrane vesicle capable of undergoing a phase transition. The bilayer membrane vesicle includes: (a) a fatty acid salt having 6 to 20 carbon atoms; (b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and (c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane. Preferably, this bilayer membrane vesicle further contains (d) a tertiary amine as a component of the membrane. Also provided is a method of inducing a phase transition of a bilayer membrane vesicle, the method including the step of adding a dehydrating condensing agent or a dehydrating condensing agent precursor having the property of accumulating at an interface to the bilayer membrane vesicle. By causing the lipids that form a molecular aggregate to chemically change, it is possible to change the physical property and the morphology of the molecular aggregate and control the timing of phase transitions such as membrane fusion. In the membrane fusion, for example, fusion can occur without leakage of the contents of the bilayer membrane vesicle.

  提供的是一种能够经历相变的双层膜小泡。该双层膜小泡包括：(a) 6至20个碳原子的脂肪酸盐；(b) 具有6至20个碳原子的脂肪链的醇或胺化合物；以及(c) 能够形成双层膜的人工合成脂质或磷脂。最好，该双层膜小泡还包含(d) 作为膜组分的三级胺。还提供了一种诱导双层膜小泡相变的方法，该方法包括向双层膜小泡添加具有在界面处积累性质的脱水缩合剂或脱水缩合剂前体的步骤。通过使形成分子聚集体的脂质发生化学变化，可以改变分子聚集体的物理性质和形态，并控制膜融合等相变的时间。例如，在膜融合中，可以在不泄漏双层膜小泡内容物的情况下发生融合。
• MOLECULAR AGGREGATE CAPABLE OF UNDERGOING PHASE TRANSITION BY DEHYDRATING CONDENSATION AND METHOD OF PHASE TRANSITION THEREOF
  申请人：Japan Science and Technology Agency

  公开号：EP1852177A1

  公开（公告）日：2007-11-07

  The present invention provides a bilayer membrane vesicle capable of undergoing a phase transition, and the bilayer membrane vesicle comprises as components of the membrane, (a) a fatty acid salt having 6 to 20 carbon atoms; (b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and (c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane. Preferably, this bilayer membrane vesicle further comprises (d) a tertiary amine as a component of the membrane. The present invention also provides a method of inducing a phase transition of a bilayer membrane vesicle, the method comprising a step of adding a dehydrating condensing agent or a dehydrating condensing agent precursor having property of accumulating at an interface to the bilayer membrane vesicle. According to the present invention, by causing the lipids that form a molecular aggregate to chemically change, it is possible to change the physical property and the morphology of the molecular aggregate and control the timing of phase transitions such as membrane fusion. In the membrane fusion, for example, fusion can occur without leaking out the contents of the bilayer membrane vesicle.

  本发明提供了一种能够发生相变的双层膜囊泡，该双层膜囊泡包括：(a) 具有 6 至 20 个碳原子的脂肪酸盐；(b) 具有 6 至 20 个碳原子的脂肪族链的醇或胺化合物；(c) 能够形成双层膜的人工合成脂质或磷脂。最好，这种双层膜囊泡还包括(d)作为膜成分的叔胺。本发明还提供了一种诱导双层膜囊泡相变的方法，该方法包括添加脱水冷凝剂或脱水冷凝剂前体的步骤，该脱水冷凝剂或脱水冷凝剂前体具有在双层膜囊泡界面聚集的特性。根据本发明，通过使形成分子聚合体的脂质发生化学变化，可以改变分子聚合体的物理性质和形态，并控制膜融合等相变的时间。例如，在膜融合过程中，可以在不泄露双层膜囊内容物的情况下发生融合。
• PROCESS FOR PREPARING SOLID BETAINES
  申请人：ETHYL CORPORATION

  公开号：EP0570383A1

  公开（公告）日：1993-11-24